Repatha Cut Heart Attack Risk by 20% Beyond Statin Treatment
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
A real-world evidence trial found that Amgen’s injectable cholesterol drug Repatha lowered heart attack risk by 20% when statins were insufficient. The study compared it with ezetimibe, an oral generic formerly sold by Merck as Zetia.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu